» Articles » PMID: 9597163

Quantitative Prediction of in Vivo Drug Clearance and Drug Interactions from in Vitro Data on Metabolism, Together with Binding and Transport

Overview
Publisher Annual Reviews
Specialties Pharmacology
Toxicology
Date 1998 May 23
PMID 9597163
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

It is of great importance to predict in vivo pharmacokinetics in humans based on in vitro data. We summarize recent findings of the quantitative prediction of the hepatic metabolic clearance from in vitro studies using human liver microsomes, hepatocytes, or P450 isozyme recombinant systems. Furthermore, we propose a method to predict pharmacokinetic alterations caused by drug-drug interactions that is based on in vitro metabolic inhibition studies using human liver microsomes or human enzyme expression systems. Although we attempt to avoid the false negative prediction, the inhibitory effect was underestimated in some cases, indicating the possible contribution of the active transport into hepatocytes and/or interactions at the processes other than the hepatic metabolism, such as the metabolism and transport processes during gastrointestinal absorption.

Citing Articles

Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool.

Yuan T, Bi F, Hu K, Zhu Y, Lin Y, Yang J Clin Pharmacokinet. 2024; 63(8):1147-1165.

PMID: 39102093 DOI: 10.1007/s40262-024-01404-0.


The Role of CYP3A in Health and Disease.

Klyushova L, Perepechaeva M, Grishanova A Biomedicines. 2022; 10(11).

PMID: 36359206 PMC: 9687714. DOI: 10.3390/biomedicines10112686.


Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics.

Lee M, Jeong Y, Kim M, An K, Chung S Pharmaceutics. 2022; 14(6).

PMID: 35745730 PMC: 9227536. DOI: 10.3390/pharmaceutics14061157.


Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 1. Theoretical Considerations.

Wang Z, Paragas E, Nagar S, Korzekwa K Drug Metab Dispos. 2021; 49(12):1090-1099.

PMID: 34503952 PMC: 11022900. DOI: 10.1124/dmd.121.000553.


Phase 0/microdosing approaches: time for mainstream application in drug development?.

Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M Nat Rev Drug Discov. 2020; 19(11):801-818.

PMID: 32901140 DOI: 10.1038/s41573-020-0080-x.